Health Personnel AttitudeNCT05120869
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
A study testing Tailored HPV Education and Professional Skills Intervention Group in people with Health Personnel Attitude and Health Knowledge, Attitudes, Practice, run by University of Texas, El Paso at 2 sites in United States.
Trial summary
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Health Personnel Attitude, Health Knowledge, Attitudes, Practice
- What is being tested?
- Tailored HPV Education and Professional Skills Intervention Group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 161 participants
- Where
- 2 sitesUnited States
- Study dates
- 22 Dec 2023to 2 Dec 2024
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Current (in practice) or emerging (in training - medical student, resident, or fellow) healthcare provider
- Working/training or living in the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
- Have the authorization to recommend/prescribe/administer the HPV vaccine
Who cannot join
- Unaffiliated with the El Paso U.S.-Mexico Border Region (i.e., El Paso County, TX-Southern New Mexico)
- Participation in Phases I or II of the larger research project [cross-sectional phases]
- Does not identify as a current or emerging healthcare provider
- Declines or is unable to participate in the full intervention and follow-up time-points
- Unable to complete participation and activities in the English language
Trial locations and contacts
2 sites in 1 country.
United States2 sites
The University of Texas at El Paso, Border Biomedical Research Center
El Paso, Texas, 79968
Burrell College of Osteopathic Medicine
Las Cruces, New Mexico, 88001
About this study
Official title: Implementing Innovative and Strategic Approaches to Prevent and Mitigate the Deleterious Effects of HPV Across the Lifespan of Hispanics of Mexican Origin: Healthcare Provider Intervention
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV). Our hypothesis is that improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among the populations they serve.
Read the detailed description
A sample of emerging [in training] and current [in practice] health professionals from the El Paso U.S.-Mexico Border Region will be recruited to participate in a human papillomavirus (HPV) educational and professional skills intervention. Hypothesis: improving provider knowledge and communication strategies about HPV and its vaccine will reduce hesitancy and increase uptake and completion among eligible individuals through a tailored multi-media intervention to strengthen providers' ability to discuss HPV and vaccination in an informed and culturally competent manner, and increase subsequent provider recommendations.
- Being tested
- Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
- Keywords
- Healthcare Professionals, Health Personnel Knowledge, Attitudes, Practices, Healthcare Skills and Training, Human Papillomavirus Vaccination, Human Papillomavirus Cancer Screening, HPV Cancer Prevention, HPV Cancer Mitigation, Sexual and Reproductive Health, U.S.-Mexico Border Health, Behavioral Research, Community Engaged Research, Health Disparities, Health Inequities, Social Determinants of Health, Coronavirus disease 2019 (COVID-19) Pandemic
- Medical subject headings
- Behavior, Coitus, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tailored HPV Education and Professional Skills Intervention GroupBehavioural
The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
General HPV Education and Communication Skills Control GroupBehavioural
The general provider education intervention will involve audio and visual content and will be delivered in the English language.
| Study group | Role | What they receive |
|---|---|---|
| Treatment | Experimental | A tailored HPV education and professional skills intervention. Receives: Behavioral: Tailored HPV Education and Professional Skills Intervention Group |
| Control | Active comparator | General/publicly available educational materials on HPV and communication skills. Receives: Behavioral: General HPV Education and Communication Skills Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Healthcare Provider (HCP) Practices Scale Score
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5).
Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Measured: Baseline
Healthcare Provider (HCP) Practices Scale Score
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5).
Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Measured: 3 months post intervention
Healthcare Provider (HCP) Practices Scale Score
Healthcare provider practices score were assessed using an 8-item Healthcare Provider (HCP) Practices scale from the Healthcare Personnel Survey. The scale evaluated healthcare providers' HPV vaccine recommendation practices, HPV screening recommendation practices, and communication practices. Items were scored on a 5-point Likert scale ranging from Never (1) to Always (5).
Healthcare provider practices score is the average score over the 8 items, ranging from 1 to 5, with higher scores indicating better (more frequent engagement in recommended healthcare provider practices related to HPV prevention and screening).
Measured: 6 months post intervention
Secondary outcomes (2)
Human Papillomavirus (HPV) Attitude Score
Healthcare provider (HCP) attitudes toward HPV and the HPV vaccine. The 9-item HPV Vaccine Attitudes scale assessed perceived safety, perceived harm, and perceived effectiveness of the HPV vaccine. Items were rated on a 5-point Likert scale ranging from Strongly disagree (1) to Strongly agree (5).
A composite score was calculated by averaging responses across all assessed items, ranging from 1 to 5, with higher scores indicating more positive attitudes toward HPV vaccination.
Measured: Immediately post-intervention (0 months).
Human Papillomavirus (HPV) Knowledge Score
Healthcare provider (HCP) knowledge about HPV and the HPV vaccine was assessed using post-intervention scores from the Human Papillomavirus (HPV) Knowledge Scale included in the healthcare personnel survey. The 14-item HPV Knowledge scale consisted of True/False items scored as True (1) or False (0).
A composite score was calculated by averaging responses across all assessed items and multiplying the result by 100 to obtain a percentage score, ranging from 0 to 100, with higher scores indicating greater HPV-related knowledge.
Measured: Immediately post-intervention (0 months).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2021
- Study start22 Dec 2023
- Primary completion2 Dec 2024
- Study completion2 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Health Personnel AttitudeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A parallel trial design will be used to examine the effectiveness of a tailored HPV education and professional skills intervention. Emerging and current healthcare providers will be randomly assigned to one of two conditions: 1) treatment condition in which they will receive a tailored Education and Professional Skills Intervention, and 2) control condition in which they will receive general, publicly available information about HPV and communication skills. Participants will then be followed over time and the responses will be compared between groups.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 161 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Texas, El Paso
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD), Burrell College of Health Sciences
- Responsible party
- Principal investigator, Eva M. Moya, PhD, LMSW, University of Texas, El Paso
- Investigators
- Eva M Moya, PhD, LMSW, Principal investigator, The University of Texas at El Paso, Border Biomedical Research Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05120869
- Sponsor's protocol ID
- 8321
- Other IDs
- 2U54MD007592-26
- Status last verified
- Aug 2026
- First submitted
- 6 Oct 2021
- Last updated
- 25 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Collected deidentified individual participant data (IPD), all IPD that underlie results in a publication.
Publications
Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006 Apr 12;24(16):3087-94. doi: 10.1016/j.vaccine.2006.01.048. Epub 2006 Feb 9.
PubMed 16500736McRee AL, Brewer NT, Reiter PL, Gottlieb SL, Smith JS. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate. Sex Transm Dis. 2010 Apr;37(4):234-9. doi: 10.1097/OLQ.0b013e3181c37e15.
PubMed 19940807Katz ML, Krieger JL, Roberto AJ. Human papillomavirus (HPV): college male's knowledge, perceived risk, sources of information, vaccine barriers and communication. J Mens Health. 2011 Oct 1;8(3):175-184. doi: 10.1016/j.jomh.2011.04.002.
PubMed 21966351Martinez J, Cordero JI, Whitney M, LaRoche KL, Frietze G, Moya EM, Gosselink K. Web-Based Human Papillomavirus Education and Professional Skills Intervention for Health Care Providers: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Apr 3;14:e60790. doi: 10.2196/60790.
PubMed 40179382